Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,221 INR | +2.06% | +1.55% | +12.64% |
May. 27 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
May. 27 | Transcript : Aurobindo Pharma Limited, Q4 2024 Earnings Call, May 27, 2024 |
Sales 2024 | 290B 3.49B | Sales 2025 * | 314B 3.78B | Capitalization | 701B 8.43B |
---|---|---|---|---|---|
Net income 2024 | 31.73B 382M | Net income 2025 * | 38.64B 465M | EV / Sales 2024 | 2.2 x |
Net cash position 2024 * | 18.34B 221M | Net cash position 2025 * | 24.35B 293M | EV / Sales 2025 * | 2.16 x |
P/E ratio 2024 |
20.1
x | P/E ratio 2025 * |
18.1
x | Employees | 23,451 |
Yield 2024 * |
0.34% | Yield 2025 * |
0.4% | Free-Float | 47.93% |
Latest transcript on Aurobindo Pharma
1 day | +1.67% | ||
1 week | -0.16% | ||
Current month | +5.44% | ||
1 month | +5.60% | ||
3 months | +18.25% | ||
6 months | +19.70% | ||
Current year | +12.20% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 86-12-25 | |
Director of Finance/CFO | - | 12-12-31 | |
B. Adi Reddy
CMP | Compliance Officer | - | 16-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 66 | 86-12-25 | |
Founder | 66 | 86-12-25 | |
Director/Board Member | 64 | 03-05-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 6 M€ | +6.07% | - | |
0.22% | 19 M€ | +8.91% | ||
0.12% | 11 M€ | +6.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1,221 | +2.06% | 2 079 792 |
24-05-27 | 1,196 | -3.13% | 4,238,829 |
24-05-24 | 1,235 | +0.42% | 1,220,847 |
24-05-23 | 1,230 | +0.58% | 706,992 |
24-05-22 | 1,223 | +0.37% | 1,896,537 |
Delayed Quote NSE India S.E., May 28, 2024 at 05:11 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.20% | 8.43B | |
+38.51% | 727B | |
+31.84% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.77% | 243B | |
+7.93% | 205B | |
-5.64% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- AUROPHARMA Stock